Who is sponsoring NCT04305938?

NCT04305938 is sponsored by Kaligia Biosciences, LLC.

What drugs are being tested in NCT04305938?

Interventions in NCT04305938: Minimally invasive and non-invasive blood analyte measurement.

What condition does NCT04305938 study?

NCT04305938 studies Calibration and Validation of Analyte Testing System.

Is NCT04305938 still recruiting?

NCT04305938 is currently status unknown. Last updated 12 March 2020.

Last reviewed 2020-03-12 · How we verify

NCT04305938

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Human Clinical Study to Collect Calibration and Performance Data for the RBA-1 and KBS-1

Status unknown Last updated 12 March 2020

What this trial tests

trial testing Minimally invasive and non-invasive blood analyte measurement in Calibration and Validation of Analyte Testing System in 1,000 participants. Status unknown.

Timeline

1 April 2020

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Kaligia Biosciences, LLC
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	1 April 2020
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across United States

Drugs / interventions tested

Minimally invasive and non-invasive blood analyte measurement

Conditions studied

Calibration and Validation of Analyte Testing System — all drugs for Calibration and Validation of Analyte Testing System →

Sponsor

Kaligia Biosciences, LLC

Who can join

18 and older, any sex, with Calibration and Validation of Analyte Testing System. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the Kaligia Biosciences KBS Systems 1.0(b) analyte monitoring device is to measure the blood analyte levels in patients. The KBS Systems 1.0(b) device avoids the common practice of accessing the vein to draw blood for conventional laboratory analysis. Instead, the KBS Systems 1.0(b) device uses Raman Spectroscopy to acheive the measurement of various blood analytes through the use of only approximately 40µl of blood. Such a small volume of blood can be sampled via a finger prick procedure rather than needing a larger volume of blood sampled via a venipuncture. The spectra contain information of all the molecules present in the blood (RBCs, hemoglobin, glucose, sodium, potassium, etc.). From these spectra, the system is able to analyze the blood and provide results in a matter of minutes, rather than hours or even, in some cases, days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04305938 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kaligia Biosciences, LLC
Last refreshed: 12 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04305938.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing